Fuzzy role of hyperhomocysteinemia in hemodialysis patients' mortality

Biomedicine and Pharmacotherapy

Volumn 60, Issue 4, 2006, Pages 200-207

  Simic Ogrizovic, S ^a   Stosovic, M ^a   Novakovic, I ^b   Pejanovic, S ^a   Jemcov, T ^a   Radovic, M ^a   Djukanovic, L ^a  

^a CLINICAL CENTER OF SERBIA   (Serbia)

^b UNIVERSITY OF BELGRADE   (Serbia)

Author keywords

Cardiovascular morbidity and mortality; Hemodialysis; Hyperhomocysteinemia

Indexed keywords

ALBUMIN; CREATININE; FOLIC ACID; HOMOCYSTEINE; VITAMIN; VITAMIN B COMPLEX;

ADULT; ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; FOLIC ACID BLOOD LEVEL; FOLLOW UP; HEART FAILURE; HEMODIALYSIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYPERHOMOCYSTEINEMIA; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; MULTIVARIATE ANALYSIS; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RADIOIMMUNOASSAY; RISK FACTOR; SURVIVAL; VITAMIN BLOOD LEVEL; VITAMIN SUPPLEMENTATION; AGED; BLOOD; CHRONIC KIDNEY FAILURE; MIDDLE AGED; RENAL REPLACEMENT THERAPY;

ADULT; AGED; FEMALE; FOLLOW-UP STUDIES; HOMOCYSTEINE; HUMANS; HYPERHOMOCYSTEINEMIA; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; RENAL DIALYSIS;

EID: 33745009496     PISSN: 07533322     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopha.2006.03.008     Document Type: Article

References (42)

1. Raine A.E., Margeritter R., Brunner F.P., Ehrich H., Geerlings W., Landais P., et al. Report on management on renal failure in Europe XXII, 1991. Nephrol. Dial. Transplant. 7 Suppl 2 (1992) S7-S35
2. Luke R.G. Chronic renal failure-a vasculopathic state. N. Engl. J. Med. 339 (1998) 841-842
3. Bostom A.G. Culleton BF. Hyperhomocysteinemia in chronic renal disease. J. Am. Soc. Nephrol. 10 (1999) 891-900
4. Tremblay A., Bonnardeaux, Geadah D., Busque L., Lebrun M., Ouimet D., et al. Hyperhomocysteinemia in hemodialysis patients: effects of 12-month supplementation with hydrosolubile vitamins. Kidney Int. 58 (2000) 851-858
5. Massy Z.A. Hyperhomocyst(e)inemia in renal failure: what are the implication?. Nephrol. Dial. Transplant. 11 (1996) 2392-2393
6. Mudd S., Skovby F., Levy H.L., Pettigrew K.D., Wilken B., Pyerits R.E., et al. Natural history of homocysteinuria due to cystatione beta synthase deficiency. Am. J. Hum. Genet. 37 (1985) 1-25
7. Omenn G.S., Beresford S.A., and Motulsky A.G. Preventing coronary heart disease: B vitamins and homocysteine. Circulation 97 (1998) 421-424
8. Boushey C.J., Beresford S.A., Omenn G.S., and Motulsky A.G. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probale benefits of increasing folic acid intakes. JAMA 274 13 (1995) 1049-1057
9. Bostom A.G., Shemin D., Verhoef P., Nadeau M.R., Jacques P.F., Selhub J., et al. Elevated fasting total plasma homocysteine levels and cardiovascular disease outcomes in maintenance dialyses. A prospective study. Arterioscler. Thromb. Vasc. Bio. 17 (1997) 2554-2558
10. Suliman M.E., Barany P., Kalantar-Zadeh K., Lindholm B., and Stenvinkel P. Homocysteine in uremia-a puzzling and conflicting story. Nephrol. Dial. Transplant. 20 (2004) 16-21
11. Jungers P., Chauveau P., Bandin O., Chadofaux B., Aupetit J., Labrunie M., et al. Hyperhomocysteinemia is associated with atherosclerotic occlusive arterial accident in predialysis chronic renal failure patients. Miner. Electrolyte Metab. 23 (1997) 170-173
12. Mustapha A., Naso A., Nahlawi M., Gupta A., Arheast K.L., Jacobsen D.W., et al. Prospective study of hyperhomocisteinemia as an adverse cardiovascular risk factor in end-stage renal disease. Circulation 97 (1998) 138-141
13. Mallamaci F., Zoccali C., Tripepi G., Fermo I., Benedetto F., Cataliotti A., et al. Kidney Int. 61 (2002) 609-614
14. Suliman M., Qureshi A.R., Barany P., Stenvikel P., Filho J., Anderstam B., et al. Hyperhomocysteinemia, nutritional status, and cardiovascular risk factors in end stage renal disease. Kidney Int. 57 (2000) 1725-1735
15. Kalantar-Zadeh K., Block G., Humphreys M.H., Mcallister C.J., and Kopple J.D. A low, rather than a high, total plasma homocysteine is an indicator of poor outcome in hemodialysis patients. J. Am. Soc. Nephrol. 15 (2004) 442-453
16. Kalantar-Zadeh K., Block G., Humphreys H., and Kopple J.D. Reverse epidemiology of cardiovascular risk factors in maintenance dialysis patients. Kidney Int. 63 (2003) 793-808
17. Kopple J.D. The phenomenon of altered risk factor patterns or reverse epidemiogy in persons with advanced chronic kidney failure. Am. J. Clin. Nutr. 81 (2005) 1257-1266
18. Bayes B., Pastor M.C., Bonal J., and Romero R. "New" cardiovascular risk factor in patient with chronic kidney disease: Role of folic acid treatment. Kidney Int. 93 (2005) S39-S43
19. Blake P., and Daugirdas. Quantification and prescription general principles. In: Jacobs C., Kjellstrand C.M., Koch K.M., and Winchester J.F. (Eds). Replacment of renal function by dialysis (1996), Kluwer Academic Publishers, Dordrecht 619-656
20. Frosst P., Blom H.J., Milos R., Goyette P., Shepard C.A., Mattews R.G., et al. A candidate genetic risk for vascular disease: a common mutation in methylene tetrahydrofolate reductase. Nat. Genet. 10 (1995) 111-113
21. McCully K.S. Homocysteine and vascular disease. Nat. Med. 2 (1996) 386-389
22. 12 , erythrocyte folate in peritoneal dialysis patients. Clin. Nephrol. 55 (2001) 313-317
23. Mustapha A., Gupta A., Robinson K., Arheart K., Jacobsen D.W., Schreiber M.J., et al. Prevalence and determinants of hyperhomocysteinema in hemodialysis patients. Kidney Int. 55 (1999) 1470-1475
24. Manns B., Burgess E., Hyndman M.E., Parsons H.G., Schefer J.P., and Scott-Douglas N.W. Hyperhomocyeinemia and the prevalence of atherosclerotic vascular disease in patients with end stage renal failure. Am. J. Kidney Dis. 4 (1999) 669-677
25. House A., Wells G., Donnely J., Nadler S., and Hebert P. Randomized trial of high-flux vs low-flux haemodalysis: effects on homocysteine and lipids. Nephrol. Dial. Transplant. 15 (2000) 1029-1034
26. Arnatodir M., Berg A.L., Hegbrant J., and Hultberg B. Influence of haemodyalisis plasma total homocysteine concentration. Nephrol. Dial. Transplant. 14 (1999) 142-146
27. Gonella M., Calabrese A., Mengozzi A., Aleo A.G., Mazzotta A., and Deambrogio P. The achievement of normal homocysteinemia in regular extracorporeal dialysis patients. J. Nephrol. 17 (2004) 411-413
28. 12 . Nephrol. Dial. Transplant. 17 (2002) 455-461
29. Bostom A.G., Shemin D., Lapane K.L., Hume A.L., Yoburn D., Nadeau M.R., et al. High dose B-vitamin treatment of hyperhomocysteinemia in dialysis patients. Kidney Int. 49 (1996) 147-152
30. Janssen M.J., Van Guldner C., De Jing G.M.M., Van Den Berg M., Stehouver C.D.A., and Donker A.J.M. Folic acid treatment of hyperhomocysteinemia in dialysis patients. Miner. Electrolyte Metab. 22 (1996) 110-114
31. Markoff R., Dwyer J., and Rocco M. Folic acid, pyridoxine, cobalamin and homocystein and their relationship to cardiovascular disease in end-stage renal disease. J. Ren. Nutrit. 6 (1996) 2-11
32. 12 on homocysteine plasma concentration in hemodialysis patients. Clin. Nephrol. 61 2 (2004) 161-162
33. Touam M., Zingraff J., Jungers P., Chadefaux-Vekemans B., Drueke T., and Massy Z. Effective correction of hyperhomocysteinemia in hemodialysis patients by intravenous folinic acid and pyridoxine therapy. Kidney Int. 56 (1999) 2292-2296
34. Buccianti G., Baragetti I., Bamonti F., Furiani S., Dorighet V., and Patrosso C. Plasma homocysteine levels and cardiovascular mortality in patients with end-stage renal disease. J. Nephrol. 17 (2004) 405-410
35. Wrone E., Zehneder J., Hornerberger J., McCann L., Coplon N., and Fortmann S. An MTHFR variant, homocysteine, and cardiovascular comorbidity in renal disease. Kidney Int. 60 (2001) 1106-1113
36. Levine B., Kalman J., Mayer L., Fillit H.M., and Oacker M. Elevated circulating levels of tumor necrosis factor in sever chronic heart failure. N. Engl. J. Med. (1990) 323-341
37. Feldman A.M., Combes A., Wagner N., Kadakomi T., Kubota T., Li Y.Y., et al. The role of tumor necrosis factor in pathophysiology of heart failure. J. Am. Coll. Cardiol. 35 (2000) 537-544
38. Pescoits-Filho R., Lindholm B., and Stenvinkel P. The malnutrition, inflammation, and atherosclerosis (MIA) syndrome-the heart of the matter. Nephrol. Dial. Transplant. 17 Suppl 11 (2002) 28-31
39. Stenvikel P., Heimburger O., Lidholm B., Kaysen G.A., and Bergstom J. Are there two types of malnutrition in chronic renal failure? Evidence for relationships between malnutrition, inflammation and atherosclerosis. (MIA syndrome). Nephrol. Dial. Transplant. 15 (2000) 953-960
40. Andreucci V.E., Fissell R.B., Bragg-Gresham J.L., Ethier J., Greenwood R., Pauly M., et al. Dialysis Outcomes and Practice Patterns Study (DOPPS) data on medications in hemodyalisis patients. Am. J. Kidney Dis. 44 Suppl 3 (2004) 61-67
41. Verhaar M.C., Stroes E., and Rabelink T.J. Folate and cardiovascular disease. Arterioscler. Thromb. Vasc. Biol. 22 (2002) 6-13
42. Silverman M.D., Tmumulluri R.J., Davis M.J., Lopez G., Rosenbaum J.T., and Lelkes P.I. Homocysteine up-regulates vascular cell adhesion molecule-1 expression in cultured human aortic endothelial cells and enhances monocytes adhesion. Arteriocler. Thromb. Vasc. Biol. 22 (2002) 587-592